Literature DB >> 28674028

Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.

Erin M Guest1, Richard Aplenc2, Lillian Sung3, Susana C Raimondi4, Betsy A Hirsch5, Todd A Alonzo6, Robert B Gerbing7, Yi-Cheng Jim Wang7, Samir B Kahwash8, Amy Heerema-McKenney9, Soheil Meshinchi10, Alan S Gamis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28674028      PMCID： PMC5561899          DOI： 10.1182/blood-2017-01-762336

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.

Authors:  Henrik Hasle; Jonas Abrahamsson; Erik Forestier; Shau-Yin Ha; Jesper Heldrup; Kirsi Jahnukainen; Ólafur Gísli Jónsson; Birgitte Lausen; Josefine Palle; Bernward Zeller
Journal:  Blood       Date:  2012-06-22       Impact factor: 22.113

2.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

3.  Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.

Authors:  H Kawasaki; K Isoyama; M Eguchi; S Hibi; N Kinukawa; Y Kosaka; T Oda; M Oda; S Nishimura; M Imaizumi; T Okamura; T Hongo; H Okawa; S Mizutani; Y Hayashi; I Tsukimoto; N Kamada; E Ishii
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

4.  Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.

Authors:  Carol O'Hear; Hiroto Inaba; Stanley Pounds; Lei Shi; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Elaine Coustan-Smith; Dario Campana; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860

5.  Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

Authors:  Robert J Arceci; Jane Sande; Beverly Lange; Kevin Shannon; Janet Franklin; Raymond Hutchinson; Terry A Vik; David Flowers; Richard Aplenc; Mark S Berger; Matthew L Sherman; Franklin O Smith; Irwin Bernstein; Eric L Sievers
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

6.  Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia.

Authors:  D K Webb; G Harrison; R F Stevens; B G Gibson; I M Hann; K Wheatley
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.

Authors:  Dror Sayar; Yoav Burstein; Bela Bielorai; Amos Toren; Rina Dvir
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

8.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.

Authors:  C M Zwaan; D Reinhardt; H Jürgens; D R Huismans; K Hählen; O P Smith; A Biondi; E R van Wering; J Feingold; G J L Kaspers
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

9.  Prognostic factors in infants with acute myeloid leukemia.

Authors:  C H Pui; S C Raimondi; D K Srivastava; X Tong; F G Behm; B Razzouk; J E Rubnitz; J T Sandlund; W E Evans; R Ribeiro
Journal:  Leukemia       Date:  2000-04       Impact factor: 11.528

10.  Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; Craig A Hurwitz; Robert J Wells; Irwin Bernstein; Patrick Buckley; Kathleen Krimmel; Franklin O Smith; Eric L Sievers; Robert J Arceci
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544
View more
  5 in total

Review 1.  Acute Leukemia in Infants.

Authors:  Azada Ibrahimova; Lauren Pommert; Erin H Breese
Journal:  Curr Oncol Rep       Date:  2021-02-12       Impact factor: 5.075

2.  Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia.

Authors:  Azada Ibrahimova; Lena E Winestone; Tamara P Miller; Kyle Kettler; Alix E Seif; Yuan-Shung Huang; Caitlin W Elgarten; Regina M Myers; Brian T Fisher; Richard Aplenc; Kelly D Getz
Journal:  Pediatr Blood Cancer       Date:  2021-03-11       Impact factor: 3.167

3.  Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia.

Authors:  Benoît Brethon; Elodie Lainey; Aurélie Caye-Eude; Audrey Grain; Odile Fenneteau; Karima Yakouben; Julie Roupret-Serzec; Lou Le Mouel; Hélène Cavé; André Baruchel
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

4.  Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios.

Authors:  Kun-Yin Qiu; Xiong-Yu Liao; Yong Liu; Ke Huang; Yang Li; Jian-Pei Fang; Dun-Hua Zhou
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

5.  Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jessica A Pollard; Erin Guest; Todd A Alonzo; Robert B Gerbing; Mike R Loken; Lisa Eidenschink Brodersen; E Anders Kolb; Richard Aplenc; Soheil Meshinchi; Susana C Raimondi; Betsy Hirsch; Alan S Gamis
Journal:  J Clin Oncol       Date:  2021-05-28       Impact factor: 50.717
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.